891 results on '"Zolla-Pazner, Susan"'
Search Results
2. Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study
3. Dynamics and durability of HIV-1 neutralization are determined by viral replication
4. Immune profiles to distinguish hospitalized versus ambulatory COVID-19 cases in older patients
5. HIV-1 Vpu restricts Fc-mediated effector functions in vivo
6. Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines
7. A tale of four studies: HIV vaccine immunogenicity and efficacy in clinical trials
8. Robust and Specific Secretory IgA Against SARS-CoV-2 Detected in Human Milk
9. Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research
10. Extended antibody-framework-to-antigen distance observed exclusively with broad HIV-1-neutralizing antibodies recognizing glycan-dense surfaces
11. Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses
12. Anti-V2 antibody deficiency in individuals infected with HIV-1 in Cameroon
13. Pre-Clinical Evaluation of a 213Bi-Labeled 2556 Antibody to HIV-1 gp41 Glycoprotein in HIV-1 Mouse Models as a Reagent for HIV Eradication
14. Corrigendum: Vaccination with immune complexes modulates the elicitation of functional antibodies against HIV-1
15. Vaccination with immune complexes modulates the elicitation of functional antibodies against HIV-1
16. Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo
17. Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination
18. Immune Correlates of Disease Progression in Linked HIV-1 Infection
19. Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV
20. Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides
21. A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site
22. Antibody Recognition of CD4-Induced Open HIV-1 Env Trimers
23. Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses
24. A critical question for HIV vaccine development: Which antibodies to induce?
25. Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking
26. Cross-neutralizing activity of human anti-V3 monoclonal antibodies derived from non-B clade HIV-1 infected individuals
27. Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2
28. Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals
29. Quantitative assessment of masking of neutralization epitopes in HIV-1
30. A single amino acid substitution in the C4 region in gp120 confers enhanced neutralization of HIV-1 by modulating CD4 binding sites and V3 loop
31. Impact of IgG Isotype on the Induction of Antibody-Dependent Cellular Phagocytosis of HIV by Human Milk Leukocytes
32. The IgA in milk induced by SARS-CoV-2 infection is comprised of mainly secretory antibody that is neutralizing and highly durable over time
33. FCGR2C polymorphisms associate with hiv-1 vaccine protection in rv144 trial
34. Non-neutralizing antibody functions for protection and control HIV in humans and SIV and SHIV in non-human primates
35. Antibodies Targeting the Envelope of HIV-1
36. Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold
37. Characterization of a Discontinuous Epitope of the HIV Envelope Protein gp120 Recognized by a Human Monoclonal Antibody Using Chemical Modification and Mass Spectrometric Analysis
38. Combined Use of Serum and Urinary Antibody for Diagnosis of Tuberculosis
39. HIV-1 Vpu restricts Fc-mediated effector functions in vivo
40. Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice
41. High Levels of Antibodies to the CD4 Binding Domain of Human Immunodeficiency Virus Type 1 Glycoprotein 120 Are Associated with Faster Disease Progression
42. Detection of Antibody Responses Against SARS-CoV-2 in Plasma and Saliva From Vaccinated and Infected Individuals
43. A fully human antibody to gp41 selectively eliminates HIV-infected cells that transmigrated across a model human blood brain barrier
44. Structural Basis of the Cross-Reactivity of Genetically Related Human Anti-HIV-1 mAbs: Implications for Design of V3-Based Immunogens
45. A Longitudinal Study of Neutralizing Antibodies and Disease Progression in HIV-1-Infected Subjects
46. Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1
47. Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope
48. Generation of Human Monoclonal Antibodies to Human Immunodeficiency Virus
49. Production of Site-Selected Neutralizing Human Monoclonal Antibodies Against the Third Variable Domain of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein
50. Nonrandom Development of Immunologic Abnormalities after Infection with Human Immunodeficiency Virus: Implications for Immunologic Classification of the Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.